JP2020521797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521797A5 JP2020521797A5 JP2019566199A JP2019566199A JP2020521797A5 JP 2020521797 A5 JP2020521797 A5 JP 2020521797A5 JP 2019566199 A JP2019566199 A JP 2019566199A JP 2019566199 A JP2019566199 A JP 2019566199A JP 2020521797 A5 JP2020521797 A5 JP 2020521797A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- seq
- treatment
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 229940126062 Compound A Drugs 0.000 claims 15
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 230000003463 hyperproliferative effect Effects 0.000 claims 6
- 230000000771 oncological effect Effects 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000004614 tumor growth Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174323.0 | 2017-06-02 | ||
| EP17174323 | 2017-06-02 | ||
| EP17196949.6 | 2017-10-17 | ||
| EP17196949 | 2017-10-17 | ||
| PCT/EP2018/064445 WO2018220169A1 (en) | 2017-06-02 | 2018-06-01 | Anti-cancer combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521797A JP2020521797A (ja) | 2020-07-27 |
| JP2020521797A5 true JP2020521797A5 (OSRAM) | 2021-07-26 |
Family
ID=62386492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566199A Pending JP2020521797A (ja) | 2017-06-02 | 2018-06-01 | 抗がん剤組み合わせ治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11198726B2 (OSRAM) |
| EP (1) | EP3630822A1 (OSRAM) |
| JP (1) | JP2020521797A (OSRAM) |
| KR (1) | KR20200013231A (OSRAM) |
| CN (1) | CN110691790A (OSRAM) |
| AU (1) | AU2018277227A1 (OSRAM) |
| BR (1) | BR112019022074A2 (OSRAM) |
| CA (1) | CA3061053A1 (OSRAM) |
| CL (1) | CL2019003430A1 (OSRAM) |
| IL (1) | IL270905A (OSRAM) |
| MX (1) | MX2019014199A (OSRAM) |
| PH (1) | PH12019502692A1 (OSRAM) |
| WO (1) | WO2018220169A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703458UA (en) * | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| CN107074941A (zh) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 双特异性抗体和用于眼科学的方法 |
| BR112019022074A2 (pt) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| JP2023550591A (ja) | 2020-11-02 | 2023-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| MX2023005192A (es) | 2020-11-04 | 2023-05-15 | Heidelberg Pharma Res Gmbh | Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer. |
| AU2022236461A1 (en) | 2021-03-19 | 2023-10-05 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
| KR20240048555A (ko) * | 2021-09-10 | 2024-04-15 | 소테르 바이오파마 피티이. 리미티드 | 항 ang2 항체 및 그 제조방법과 응용 |
| AU2023374571A1 (en) | 2022-11-01 | 2025-04-03 | Heidelberg Pharma Research Gmbh | Anti-gucy2c antibody and uses thereof |
| WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| EP2316951A1 (en) | 2001-01-17 | 2011-05-04 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| JP5113523B2 (ja) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| WO2009109635A2 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EA031182B1 (ru) * | 2012-03-30 | 2018-11-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Ang2-связывающие молекулы |
| KR20150060687A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물 |
| EA201500371A1 (ru) * | 2012-09-28 | 2015-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3286217A1 (en) | 2015-04-23 | 2018-02-28 | F. Hoffmann-La Roche AG | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death ligand 1 |
| WO2016170039A1 (en) | 2015-04-23 | 2016-10-27 | F. Hoffmann-La Roche Ag | Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| WO2017165681A1 (en) | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| MX393609B (es) * | 2016-05-18 | 2025-03-24 | Boehringer Ingelheim Int | Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer |
| BR112019022074A2 (pt) * | 2017-06-02 | 2020-05-12 | Boehringer Ingelheim International Gmbh | Terapia de combinação anticâncer |
| US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
-
2018
- 2018-06-01 BR BR112019022074-7A patent/BR112019022074A2/pt not_active IP Right Cessation
- 2018-06-01 CA CA3061053A patent/CA3061053A1/en active Pending
- 2018-06-01 JP JP2019566199A patent/JP2020521797A/ja active Pending
- 2018-06-01 EP EP18727819.7A patent/EP3630822A1/en not_active Ceased
- 2018-06-01 KR KR1020197035427A patent/KR20200013231A/ko not_active Withdrawn
- 2018-06-01 AU AU2018277227A patent/AU2018277227A1/en not_active Abandoned
- 2018-06-01 WO PCT/EP2018/064445 patent/WO2018220169A1/en not_active Ceased
- 2018-06-01 US US15/995,375 patent/US11198726B2/en active Active
- 2018-06-01 CN CN201880036511.5A patent/CN110691790A/zh active Pending
- 2018-06-01 MX MX2019014199A patent/MX2019014199A/es unknown
-
2019
- 2019-11-25 CL CL2019003430A patent/CL2019003430A1/es unknown
- 2019-11-25 IL IL270905A patent/IL270905A/en unknown
- 2019-11-28 PH PH12019502692A patent/PH12019502692A1/en unknown
-
2021
- 2021-11-08 US US17/520,748 patent/US20220340651A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020521797A5 (OSRAM) | ||
| JP2024029009A5 (OSRAM) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| CA2856646C (en) | Combination treatment of cancer | |
| JP2020518599A5 (OSRAM) | ||
| JP2018109022A5 (OSRAM) | ||
| JP2019517549A5 (OSRAM) | ||
| JP2010270124A5 (OSRAM) | ||
| JP2013533858A5 (OSRAM) | ||
| JP2014509659A5 (OSRAM) | ||
| IL273169B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| JP2006523216A5 (OSRAM) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2015534578A5 (OSRAM) | ||
| JP2015526458A5 (OSRAM) | ||
| JP2013507415A5 (OSRAM) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP6063550B2 (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2019534003A5 (OSRAM) | ||
| JP2018529661A5 (OSRAM) | ||
| TW201313228A (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| JP2019534251A5 (OSRAM) |